When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research. Jacobs, E., Murphy-Beiner, A., Rouiller, I., Nutt, D., & Spriggs, M. J. Neuroethics, 17(1):3, November, 2023.
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research [link]Paper  doi  abstract   bibtex   
The ethical value—and to some scholars, necessity—of providing trial patients with post-trial access (PTA) to an investigational drug has been subject to significant attention in the field of research ethics. Although no consensus has emerged, it seems clear that, in some trial contexts, various factors make PTA particularly appropriate. We outline the atypical aspects of psychedelic clinical trials that support the case for introducing the provision of PTA within research in this field, including the broader legal status of psychedelics, the nature of the researcher-therapist/participant relationship, and the extended time-frame of the full therapeutic process. As is increasingly understood, the efficacy of psychedelic-assisted psychotherapy is driven as much by extrapharmacological elements and the cultural therapeutic container as by the drug itself. As such, we also advocate for a refocusing of attention from post-trial access to a broader concept encompassing other elements of post-trial care. We provide an overview of some of the potential post-trial care provisions that may be appropriate in psychedelic clinical trials. Although the World Medical Association’s Declaration of Helsinki calls on researchers, sponsors, and governments to make provisions for post-trial access, such provision may feel impracticable or out-of-reach within psychedelic trials that are already constrained by a high resource demand and significant bureaucratic burden. We show how conceiving of post-trial provision as an integral site of the research process, and an appropriate destination for research funding, will serve to develop the infrastructure necessary for the post-legalisation psychedelic medicine ecosystem.
@article{jacobs_when_2023,
	title = {When the {Trial} {Ends}: {The} {Case} for {Post}-{Trial} {Provisions} in {Clinical} {Psychedelic} {Research}},
	volume = {17},
	issn = {1874-5504},
	shorttitle = {When the {Trial} {Ends}},
	url = {https://doi.org/10.1007/s12152-023-09536-z},
	doi = {10.1007/s12152-023-09536-z},
	abstract = {The ethical value—and to some scholars, necessity—of providing trial patients with post-trial access (PTA) to an investigational drug has been subject to significant attention in the field of research ethics. Although no consensus has emerged, it seems clear that, in some trial contexts, various factors make PTA particularly appropriate. We outline the atypical aspects of psychedelic clinical trials that support the case for introducing the provision of PTA within research in this field, including the broader legal status of psychedelics, the nature of the researcher-therapist/participant relationship, and the extended time-frame of the full therapeutic process. As is increasingly understood, the efficacy of psychedelic-assisted psychotherapy is driven as much by extrapharmacological elements and the cultural therapeutic container as by the drug itself. As such, we also advocate for a refocusing of attention from post-trial access to a broader concept encompassing other elements of post-trial care. We provide an overview of some of the potential post-trial care provisions that may be appropriate in psychedelic clinical trials. Although the World Medical Association’s Declaration of Helsinki calls on researchers, sponsors, and governments to make provisions for post-trial access, such provision may feel impracticable or out-of-reach within psychedelic trials that are already constrained by a high resource demand and significant bureaucratic burden. We show how conceiving of post-trial provision as an integral site of the research process, and an appropriate destination for research funding, will serve to develop the infrastructure necessary for the post-legalisation psychedelic medicine ecosystem.},
	language = {en},
	number = {1},
	urldate = {2024-01-18},
	journal = {Neuroethics},
	author = {Jacobs, Edward and Murphy-Beiner, Ashleigh and Rouiller, Ian and Nutt, David and Spriggs, Meg J.},
	month = nov,
	year = {2023},
	keywords = {Clinical trials, Post-trial access, Psilocybin, Psychedelic, Research ethics},
	pages = {3},
}

Downloads: 0